Gilead bags EU approval for Sovaldi; Google gets into med tech;

@FierceBiotech: Auspex's $76M IPO pitch tests the limits of biotech's window. Story | Follow @FierceBiotech

@JohnCFierce: ICYMI: Roche 's dealmakers at pRED will continue their global shopping spree in 2014. Piece | Follow @JohnCFierce

@DamianFierce: Welcome back, Ariad: Iclusig returns after a cold winter. More Follow @DamianFierce

@EmilyMFierce: Experimental microparticle therapy could treat inflammatory conditions, from effects of heart attack to diabetes. Article | Follow @EmilyMFierce

> Gilead ($GILD) picked up EU approval for Sovaldi, its pioneering treatment for hepatitis C. More

> With 2014's J.P. Morgan Healthcare Conference coming to a close, Atlas Venture Partner Bruce Booth has compiled his observations and incites heading into the new year. Post

> Google ($GOOG) is getting into med tech with plans for a glucose-monitoring contact lens. Story

Medical Device News

@FierceMedDev: Boston Scientific won't begin its U.S. hypertension study until it reviews Medtronic's setback. More | Follow @FierceMedDev

@MarkHFierce: Google is developing a contact lens that monitors glucose levels. Partners needed to bring the product to market. Story | Follow @MarkHFierce

@MichaelGFierce: Study: Carotid stents, regardless of origin, are similarly effective at preventing stroke, death. Item | Follow @MichaelGFierce

@EmilyWFierce: Flu season predictions from scientists at Columbia could help you stay out of bed. Article | Follow @EmilyWFierce

@GalenMoore: Here's who was in the room when a team from Google X met with FDA officials last month. | Follow @GalenMoore

> A (now) broken record: Med tech VC funding dropped again in 2013. News

> BioMérieux closes BioFire Diagnostics deal for $450M plus debt. Story

Pharma News

@FiercePharma: Big Pharma accused of hatching 'satanic plot' in South Africa. More | Follow @FiercePharma

@TracyStaton: Trending at FiercePharma: Novartis may finally face generic competition for Diovan. Yesterday's story | Follow @TracyStaton

@EricPFierce: FDA investigator assigned to Europol to fight fakes being hawked online by drug rings. Story from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI: Look for Teva's new chief to move fast on dealmaking, CFO says. Story | Follow @CarlyHFierce

> FDA advisory panel gives J&J's Xarelto resounding 'no' for ACS. Story

> Roche resolves shortage of liquid Tamiflu. Article

> Gilead's Sovaldi rolls on with approval in EU. Item

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.